Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
Experimental drugs have extremely limited human consumption data. There is not enough reliable information about this substance. This is most likely because the substance is is not very old. Information on these substances is limite and incomplete. Please be cautioned. Always practice harm reduction.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
A new psychedelic lysergamide which is suspected to be a prodrug of ETH-LAD, which could explain why the doses are very similar. Or it could be active on its own. Scientific studies would need to be written to understand, yet there are none.
It is a designer drug analog and suspected prodrug to ETH-LAD, which shares a close structural relationship with LSD and 1P-LSD. Anecdotal reports suggest that this compound produces largely similar psychedelic effects comparable to ETH-LAD or AL-LAD. Like its parent compound ETH-LAD, this compound has been reported to be moderately to significantly more potent than LSD itself.
It has also been reported as being subtly different in effect to LSD and is often described as being more visual and synaesthetic, with a deeper, less emotionally-charged headspace analogous to that of psychedelics like 2C-E or DPT. It has also been reported to be more likely to induce undesirable effects like anxiety, thought loops in addition to pronounced nausea and other discomforting physical effects it displays relative to other lysergamides. Very little data exists about the pharmacological properties, metabolism, and toxicity of 1P-ETH-LAD, and it has little history of human usage before January 2016.
It has recently become commonly marketed alongside other designer psychedelics such as 1P-LSD and ETH-LAD as a legal alternative to LSD and is commercially distributed through online research chemical vendors.
1P-ETH-LAD is a structural analog of lysergic acid, with an N, N-diethylamide functional group bound to RN of the chemical structure.
This core polycyclic structure is an ergoline derivative and has tryptamine and phenethylamine groups embedded within it. 1P-ETH-LAD’s structure contains a bicyclic hexahydro indole fused to a bicyclic quinoline group (nor-lysergic acid).
1P-ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton; the nor- prefix represents this.
Instead, 1P-ETH-LAD is substituted at R6 with an ethyl group and at R1 with a propionyl group.
At carbon 8 of the quinoline, an N, N-diethyl carboxamide is bound. 1P-ETH-LAD is a chiral compound with two stereocenters at R5 and R8.
1P-ETH-LAD, also called (+)-D-1P-ETH-LAD, has an absolute configuration of (5R, 8R).
The three other stereoisomers of 1P-ETH-LAD have not been shown to possess psychoactive properties.
|1P-ETH-LAD Duration Data|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Marguis Test Result|
This compound likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from 1P-ETH-LAD’s efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. 1P-ETH-LAD shares many common traits with its parent compound LSD; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. Research has shown formation of ETH-LAD from 1P-ETH-LAD incubated in human serum, suggesting that it functions as a pro-drug.
- Stimulation - 1P-ETH-LAD is usually considered to be very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocin are sedating and relaxing.
- Spontaneous bodily sensations - The "body high" of 1P-ETH-LAD can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, it is a little less sharp in its tingles, less likely to be uncomfortable but otherwise essentially identical.
- Bodily control enhancement
- Increased heart rate
- Nausea - Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly once the tripper has vomited or gradually fades by itself as the peak sets in.
- Pupil dilation
- Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most 1P-ETH-LAD trips.
- Teeth grinding
- Temperature regulation suppression
- Analysis enhancement
- Conceptual thinking
- Déjà vu
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Motivation enhancement
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought loops
- Time distortion
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance. This is nearly identical in appearance to the visual drifting which occurs under the influence of LSD
- After images
- Colour shifting
- Depth perception distortions
- Scenery slicing
- Symmetrical texture repetition
1P-ETH-LAD visual geometry can be described as more similar in appearance to that of LSD, 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, organic in feel, multicoloured in scheme, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in-depth and consistent in intensity. At higher dosages, it consistently results in states of level 8B visual geometry over level 8A.
In comparison to LSD specifically, its geometry tends to be more rounded in its corners, slightly softer in its edges and a little less intricate in its form. Aside from this, it is otherwise identical in its appearance.
1P-ETH-LAD is capable of producing a full range of low and high-level hallucinatory states in a fashion that is a little less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely when to compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavier dosages. These effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. The hallucinations can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and occasionally of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
It is unclear in many countries whether this compound is legal or not and one should take precaution by assuming it is illegal to avoid legal issues.
- "1P-ETH-LAD (Google Trends)". Retrieved January 1, 2020.
- Nichols, David E. (2017). "Chemistry and Structure–Activity Relationships of Psychedelics". In Halberstadt, Adam L.; Vollenweider, Franz X.; Nichols, David E. Behavioral Neurobiology of Psychedelic Drugs. pp. 1–43. :10.1007/7854_2017_475. 978-3-662-55878-2.
- Brandt, S. D.; Kavanagh, P. V.; Westphal, F.; Elliott, S. P.; Wallach, J.; Stratford, A.; Nichols, D. E.; Halberstadt, A. L. (2017). "Return of the lysergamides. Part III: Analytical characterization of N6‐ethyl‐6‐norlysergic acid diethylamide (ETH‐LAD) and 1‐propionyl ETH‐LAD (1P–ETH‐LAD)". Drug Testing and Analysis. 9 (10): 1641–1649. :10.1002/dta.2196. 1942-7611.
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1556-9039.
- "Precursor Control Regulations (SOR/2002-359) - SCHEDULE". Government of Canada. Retrieved January 1, 2020.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Psychoactive Substances Act 2016". UK Government. Retrieved January 1, 2020.
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.